NO970369L - Identifikasjon av en human cytomegalovirus-genregion involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon - Google Patents

Identifikasjon av en human cytomegalovirus-genregion involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon

Info

Publication number
NO970369L
NO970369L NO970369A NO970369A NO970369L NO 970369 L NO970369 L NO 970369L NO 970369 A NO970369 A NO 970369A NO 970369 A NO970369 A NO 970369A NO 970369 L NO970369 L NO 970369L
Authority
NO
Norway
Prior art keywords
heavy chain
downregulation
mhc class
human cytomegalovirus
identification
Prior art date
Application number
NO970369A
Other languages
English (en)
Other versions
NO970369D0 (no
Inventor
Ann E Campbell
Thomas R Jones
Original Assignee
American Cyanamid Co
Ann E Campbell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co, Ann E Campbell filed Critical American Cyanamid Co
Publication of NO970369D0 publication Critical patent/NO970369D0/no
Publication of NO970369L publication Critical patent/NO970369L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C07K14/045—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Identifikasjon av en human cytomegalovirus-genregion involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon Infeksjon av humane fibroblasl-celler med humant cytomegalovirus (HCMV) forårsaker nedregulering av celleoverflate-ekspresjon av MHC-klasse I, Fore- liggende oppfinnelse angår en 9-kb delesjon i S-komponenten av HCMV-genomet (omfattende åpne leserammer IRS-1 - US9 og US11) som ikke kan nedregulere klasse-l-tungkjeder. Ved å undersøke fenotypene til mutanter med mindre delesjoner med denne delen av HCMV-genomet, ble en 7-kb region som omfatter i det minste 9 åpne leserammer vist å inneholde genene som er nødvendig for reduksjon i tungkjede-ekspresjon. Videre ble del bestemt at lo subregioner (A og B) i 7-kb-regionen begge inneholdt gener som er tilstrekkelige til å gi tungkjede- nedregulering. I subregion B er US11-genproduktet involvert. Det koder for et endoglykosidase-H-sensitivt glykoprotein som er intracytoplasmatisk, tilsvarende adenovirus type E3-19K glykoproteiner som inhiberer overflate-ekspresjon av klasse-l-tungkjeder.
NO970369A 1994-07-29 1997-01-28 Identifikasjon av en human cytomegalovirus-genregion involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon NO970369L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/282,696 US5846806A (en) 1994-07-29 1994-07-29 Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
PCT/US1995/009607 WO1996004383A1 (en) 1994-07-29 1995-07-28 Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression

Publications (2)

Publication Number Publication Date
NO970369D0 NO970369D0 (no) 1997-01-28
NO970369L true NO970369L (no) 1997-03-21

Family

ID=23082718

Family Applications (2)

Application Number Title Priority Date Filing Date
NO970370A NO970370L (no) 1994-07-29 1997-01-28 Identifikasjon av et human cytomegalovirusgen involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon
NO970369A NO970369L (no) 1994-07-29 1997-01-28 Identifikasjon av en human cytomegalovirus-genregion involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO970370A NO970370L (no) 1994-07-29 1997-01-28 Identifikasjon av et human cytomegalovirusgen involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon

Country Status (11)

Country Link
US (6) US5846806A (no)
EP (2) EP0775209A1 (no)
JP (2) JP4036469B2 (no)
KR (2) KR970704884A (no)
AU (2) AU709552B2 (no)
CA (3) CA2195668C (no)
FI (2) FI970352A (no)
MX (1) MX9700676A (no)
NO (2) NO970370L (no)
NZ (2) NZ290718A (no)
WO (2) WO1996004383A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032605A1 (en) * 1996-03-08 1997-09-12 Massachusetts Institute Of Technology Cytomegalovirus nucleic acids encoding proteins having normal or altered class i mhc binding and treatment of diseases
PT966301E (pt) * 1996-07-31 2005-06-30 Ortho Mcneil Pharm Inc Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i
AU6210598A (en) * 1997-01-17 1998-08-07 Boehringer Mannheim Gmbh Inhibitors of antigen presentation by mhc class i molecules
WO1998047914A2 (de) * 1997-04-18 1998-10-29 Roche Diagnostics Gmbh Us6 gen aus dem humanen cytomegalovirus (hcmv)
CA2318664A1 (en) * 1998-01-14 1999-07-22 Human Gene Therapy Research Institute Nucleotide expression systems with reduced immunogenicity for use in gene therapy
US6100008A (en) * 1998-09-14 2000-08-08 Ppg Industries Ohio, Inc. Positive photoresist with improved contrast ratio and photospeed
AU2752900A (en) * 1999-02-02 2000-08-25 Oregon Health And Science University Inhibition of the mhc class ii antigen presentation pathway and presentation to cd4+ cells
AU2001288682A1 (en) 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US20030118568A1 (en) * 2001-12-18 2003-06-26 Board Of Trustees Of The University Of Arkansas Viral stealth technology to prevent T cell-mediated rejection of xenografts
WO2004076645A2 (en) * 2003-02-27 2004-09-10 University Of Massachusetts Compositions and methods for cytomegalovirus treatment
KR20050093003A (ko) * 2004-03-17 2005-09-23 이재본 직류형 마이크로 터빈 발전기
EA200970731A1 (ru) 2007-02-07 2010-02-26 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Рекомбинантные антигены цитомегаловируса человека (hcmv)
US9592285B2 (en) 2007-11-12 2017-03-14 The Trustees Of The University Of Pennsylvania Vaccines against multiple subtypes of influenza virus
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT3351636T (pt) 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
DK2691530T3 (en) * 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
ES2696703T3 (es) 2013-03-05 2019-01-17 Univ Oregon Health & Science Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US10428118B2 (en) 2014-07-16 2019-10-01 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
AU2016219317A1 (en) * 2015-02-10 2017-08-31 Oregon Health & Science University Methods and compositions useful in generating non canonical CD8+ T cell responses
CA3005136A1 (en) 2015-11-20 2017-05-26 Oregon Health & Science University Cmv vectors comprising microrna recognition elements
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CA3028827A1 (en) 2016-06-22 2017-12-28 Aeras Recombinant cytomegalovirus vectors as vaccines for tuberculosis
MA46588A (fr) 2016-10-18 2021-04-14 Univ Oregon Health & Science Vecteurs de cytomégalovirus déclenchant des lymphocytes t limités par des molécules e de complexe majeur d'histocompatibilité
US11638749B2 (en) 2017-10-17 2023-05-02 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058598A (en) * 1974-10-18 1977-11-15 Harold Stern Cytomegalovirus attenuation method and vaccine
US4689225A (en) * 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US4877612A (en) * 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
US4877737A (en) * 1985-09-06 1989-10-31 Prutech Research And Development Partnership Attenuated pseudorabies virus which has a deletion in at least a portion of a repeat sequence and vaccine containing same
ATE118822T1 (de) * 1987-06-26 1995-03-15 Syntro Corp Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
US5273876A (en) * 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
EP0413738A1 (en) * 1988-05-09 1991-02-27 The Children's Hospital, Incorporated Vectors encoding hcmv glycoprotein and expression products
EP1092775A1 (en) * 1991-07-05 2001-04-18 American Cyanamid Company Methods for identifiying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus

Also Published As

Publication number Publication date
MX9700710A (es) 1997-09-30
US5720957A (en) 1998-02-24
NO970370D0 (no) 1997-01-28
CA2328638A1 (en) 1996-02-15
AU3153595A (en) 1996-03-04
FI970351A0 (fi) 1997-01-28
WO1996004384A1 (en) 1996-02-15
JPH10503378A (ja) 1998-03-31
JP4036469B2 (ja) 2008-01-23
FI970352A0 (fi) 1997-01-28
US5843458A (en) 1998-12-01
NO970370L (no) 1997-03-24
FI970351A (fi) 1997-01-28
CA2196207A1 (en) 1996-02-15
JPH10506268A (ja) 1998-06-23
EP0775209A1 (en) 1997-05-28
NZ290718A (en) 1999-03-29
FI970352A (fi) 1997-01-28
MX9700676A (es) 1997-04-30
AU709552B2 (en) 1999-09-02
KR970704883A (ko) 1997-09-06
AU3274595A (en) 1996-03-04
US5906935A (en) 1999-05-25
CA2196207C (en) 2002-04-30
CA2195668C (en) 2004-09-21
NZ291571A (en) 1999-01-28
US5753476A (en) 1998-05-19
KR970704884A (ko) 1997-09-06
US5846806A (en) 1998-12-08
CA2195668A1 (en) 1996-02-15
US5908780A (en) 1999-06-01
EP0772681A1 (en) 1997-05-14
WO1996004383A1 (en) 1996-02-15
AU708983B2 (en) 1999-08-19
NO970369D0 (no) 1997-01-28

Similar Documents

Publication Publication Date Title
NO970369L (no) Identifikasjon av en human cytomegalovirus-genregion involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon
Shemer et al. Structure of the imprinted mouse Snrpn gene and establishment of its parental-specific methylation pattern
Epstein et al. Expression of H‐Y antigen on preimplantation mouse embryos
GR3025961T3 (en) Amplification of human mdm2 gene in human tumors.
EA199800566A1 (ru) Аденовирусный вектор (варианты), способ его получения, применение, репликационно-компетентное не содержащее аденовирус потомство, способ повышения размножения в комплементирующей клеточной линии аденовирусного вектора, способ генетической модификации клетки, композиция, клетка-хозяин, способ тестирования токсичности аденовирусного вектора, способ тестирования экспрессии чужеродного гена или гена-пассажира аденовирусного вектора
TW369564B (en) Methods for reducing inhibition of nucleic acid amplification reactions
Furukawa et al. Animal models of spontaneous and drug-induced cutaneous lupus erythematosus
DK0879282T3 (da) Immunterapi ved anvendelse af cytotoksiske T-lymfocytter (CTL)
ES2155090T3 (es) Adenovirus defectivos.
MX9705039A (es) Genes y proteinas de muerte celular programada.
Orr et al. Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice
WO1998037185A3 (en) Vectors for controlled gene expression
WO1998004709A3 (en) Herpes simplex virus ICP4 is an inhibitor of apoptosis
DK0843731T3 (da) Adenovirusvektorer til genterapi
Simeonov et al. T cell subset-selective IL2RA enhancers shape autoimmune diabetes risk
Echchakir et al. Analysis of T‐cell‐receptor β‐chain‐gene usage in peripheral‐blood and tumor‐infiltrating lymphocytes from human non‐small‐cell lung carcinomas
Buehr et al. An electrophoretically detectable modification of glucosephosphate isomerase in mouse spermatozoa
DE69627202D1 (de) Behandlung von roten blutzellen zur inaktivierung von virien durch verwendung von pathalocyanine und rotlicht
MX9605941A (es) Procedimiento para introducir material extraño en celulas eucarioticas superiores.
DK0741791T3 (da) CD69-Tanskriptionsregulerende elementer
Lobitz et al. Giemsa banding pattern of a heritable 1q+ variant chromosome: a possible partial duplication.
Shipp Stage-specific alterations in ectodermal segment formation of Mysidopsis bahia (Crustacea, Malacostraca, Peracarida, Mysidacea) caused by macromolecular inhibitors and centrifugation.
Løvhaug et al. Regulation of bone marrow cell growth in diffusion chambers: the effect of granulocyte extracts
Bootsma Defective DNA repair and cancer
Huang et al. Expression of bcl-2 in human ocular surface epithelia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application